gamma C280-intimin and EspB, two main virulence factors from enterohemorragic Escherichia coli, can be efficiently delivered by intranasal route using the TLR2/6 agonist MALP-2 as mucosal adjuvant

YEVSA T; VILTE DA; SCHULZE K; LARZÁBAL M; IBARRA C; MERCADO EC; GUZMÁN CA; CATALDI A

Brasilia

Congreso; 24º Congresso Brasileiro de Microbiologia; 2007

  In Argentina, haemolytic uremic syndrome (HUS) is not only epidemic but also endemic, with an annual incidence of around 12.2 cases/ 100,000 children under five years of age (9). In this condition it is relevant to consider vaccines as an alternative to control this disease. Different authors have investigated the immune response against EHEC and candidate vaccines. Genetically modified Shiga toxins (Stx), toxoids and toxin subunits, and plasmids expressing Stx subunits have also been assayed as immunogens (2-4). Systemic administration of anti-Stx2 neutralising antibodies protects animals from death in experimental HUS (7;10), emphasising the importance of the humoral response as a protective mechanism in HUS. Subcutaneus immunization with type III secreted proteins decreased shedding of EHEC O157 by cattle (8). An enteropathogenic E. coli attenuated deleted truncating in intimin conferred protection against challenge with the wild strain (1). In the present study we sought to investigate the mice mucosal and systemic immune response to recombinant C280 gamma-intimin, EspA, EspB and modified Stx2B, and the modulation of the immune response by the use of the TLR2/6 agonist MALP-2 as adjuvant.